Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience

ECCO'20 Vienna

Year: 2020
Authors:

Y. Gonzalez Lama, M. Calvo, V. Matallana, I. Gonzalez-Partida, I. Omella, M.I. Vera

Department of Gastroenterology, University Hospital Puerta De Hierro, Majadahonda, Spain

P504 Remote cannabis-therapy management platform for IBD patients: performance assessment

ECCO'20 Vienna

Year: 2020
Authors:

G. Sweed1, C. Shapira2, T. Naftali3

1Clalit health care, Occupational Medicine, Haifa, Israel, 2Technion, Israel institute of technology, Haifa, Israel, 3Clalit health care, Gastroenterology, Kfar Saba, Israel

P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience

ECCO'20 Vienna

Year: 2020
Authors:

D. Rosembert1, A. Malaviya2, J. How2, J. Tomlison3, F. Toh3, M. Roe1, A. Nightingale4, C. Garcia-Sueiro4, P. Herbert4, D. Jadon2, P. Norris3, J. Thomas3, J. Magsino4, A. Negoescu2, T. Raine4

1Department of Pharmacy, Cambridge University Hospitals, Cambridge, UK, 2Department of Rheumatology, Cambridge University Hospitals, Cambridge, UK, 3Department of Dermatology, Cambridge University Hospitals, Cambridge, UK, 4Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK

P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF

ECCO'20 Vienna

Year: 2020
Authors:

H. Yanai1,2, S. Amir2, I. Avni Biron1,2, T. Tsadok Perets1,2, R. Shamir2,3, I. Dotan1,2, A. Assa2,3

1Rabin Medical Center, IBD Center- Division of Gastroenterology, Petah-Tikva, Israel, 2Tel Aviv University, Sackler Faculty of Medicine-, Tel Aviv, Israel, 3Schneider Children’s Medical Center, The Institute of Gastroenterology- Nutrition and Liver diseases, Petah Tikva, Israel

P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort

ECCO'20 Vienna

Year: 2020
Authors:

R. Gadhok1, K. Fragkos2, S. Honap3, J. Hassan2, L. Whiteley2, A. Ibarra1, N. Burgess1, R. Vega2, E. Seward2, S. Mehta2, S. McCartney2, S. Bloom2, G. Parkes1, P. Irving3, J.O. Lindsay1, K.B. Kok1, F. Rahman2

1Gastroenterology, Royal London Hospital- Barts Health NHS Trust, London, UK, 2Gastroenterology, University College London Hospital NHS Trust, London, UK, 3Gastroenterology, Guys and St Thomas’ Hospital NHS Trust, London, UK

P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study

ECCO'20 Vienna

Year: 2020
Authors:

L. Goessens1, J.F. Colombel2, A. Outtier3, M. Ferrante3, M. Truyens4, T. Lobaton4, F. Baert5, P. Bossuyt6, A. Cremer7, E. Macken8, B. Strubbe9, J.F. Rahier1

1CHU UCL Namur, Gastroenterology, Yvoir, Belgium, 2Icahn School of Medicine at Mount Sinai, Gastroenterology, New-York, USA, 3University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 4University Hospital Gent, Gastroenterology, Gent, Belgium, 5AZ Delta, Gastroenterology, Roeselare, Belgium, 6Imelda General Hospital, Gastroenterology, Bonheiden, Belgium, 7Erasme University Hospital, Gastroenterology, Bruxelles, Belgium, 8University Hospital Antwerp, Gastroenterology, Edegem, Belgium, 9AZ Sint-Lucas, Gastroenterology, Gent, Belgium

P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

W. Sun1, B. Fennimore2, D.B. Beaulieu3, R. Arsenescu4, A. Stein5, J. Chen6, T. Lin7, S. McKnight8, M. Rosario9, R.A. Lirio10

1Takeda, Quantitative Clinical Pharmacology, Cambridge, USA, 2University of Colorado, Department of Medicine Gastroenterology, Aurora, USA, 3Vanderbilt University Medical Center, Vanderbilt Digestive Disease Center, Nashville, USA, 4Morristown Medical Center, AHS Hospital Corporate, Morristown, USA, 5Northwestern University, Division of Gastroenterology and Hepatology, Chicago, USA, 6Takeda, Statistics and Quantitative Sciences, Cambridge, USA, 7Certara, Integrated Drug Development, Princeton, USA, 8Takeda, Global Program Management, Cambridge, USA, 9Takeda, Clinical Pharmacology, Cambridge, USA, 10Takeda, Clinical Science, Cambridge, USA

P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data

ECCO'20 Vienna

Year: 2020
Authors:

W. Sandborn1, D. Wolf2, G. D’haens3, J. Jansson4, J. Chen5, S. Uddin5, N. Candela6, K. Lasch6, K. Kisfalvi5

1University of California San Diego, Division of Gastroenterology, La Jolla, USA, 2Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, USA, 3University of Amsterdam- Academic Medical Center, Gastroenterology, Amsterdam, The Netherlands, 4Takeda Development Center Americas Inc-, Gastroenterology, Cambridge, USA, 5Takeda Development Center Americas Inc., Gastroenterology, Cambridge, USA, 6US Medical Office- Takeda Pharmaceuticals USA Inc., Gastroenterology, Deerfield, USA

P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial

ECCO'20 Vienna

Year: 2020
Authors:

B. Bressler1, B. Sattin2, M.A. Williamson2, R. Khanna3, C.H. Seow4, D. Dajnowiec2, K. Karra2, L.L. Gao5, W. Afif6, mUST-Decide

1Department of Gastroenterology, University of British Columbia, Vancouver, Canada, 2Department of Medical Affairs, Janssen Canada, Toronto, Canada, 3Department of Epidemiology and Biostatistics, Western University, London, Canada, 4Department of Gastroenterology, University of Calgary Calgary, Canada, 5Research and Development- LLC, Janssen Inc., Spring House, USA, 6Inflammatory Bowel Disease Centre, McGill University Health Centre, Montreal, Canada

P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data

ECCO'20 Vienna

Year: 2020
Authors:

Y. XIAO1, P.L. Lakatos2, R. Bourdages3, A. Bitton2, W. Afif2, R. Kohen2, M. Berberi3, T. Bessissow2

1Division of Internal Medicine, McGill University, Montreal, Canada, 2Division of Gastroenterology, McGill University, Montreal, Canada, 3Division of Gastroenterology, Hopital Hotel-Dieu de Lévis, Quebec City, Canada

P513 has been withdrawn

ECCO'20 Vienna

Year: 2020
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?

ECCO'20 Vienna

Year: 2020
Authors:

A. Lightner1, H. Buhulaigah2, K. Zaghiyan2, P. Vaidya1, M. Regueiro1, P. Fleshner2

1Department of Colorectal Surgery, Cleveland Clinic, Cleveland, USA, 2Cedars-Sinai, Colon and Rectal Surgery, Cleveland- OH, USA

P515 Comparability of upadacitinib pharmacokinetics in Japanese and non-Japanese subjects with ulcerative colitis with the extended-release formulation

ECCO'20 Vienna

Year: 2020
Authors:

S. Stodtmann1, A. Friedel1, W. Zhou2, M.E. MOHAMED3

1AbbVie, Clinical Pharmacology and Pharmacometrics, Ludwigshafen, Germany, 2Immunology Development, AbbVie, North Chicago, USA, 3Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, USA

P516 Daily consumers of drip-filtered coffee have a decreased risk of developing late-onset Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

L. Widbom1, J. Hultdin1, K. Ekblom2, P. Karling3, L.M. Nilsson4

1Department of Medical Biosciences- Umeå University, Clinical Chemistry, Umeå, Sweden, 2Department of Research and Development- Region Kronoberg- Växjö, Clinical Chemistry, Växjö, Sweden, 3Department of Public Health and Clinical Medicine- Umeå University, Medicine, Umeå, Sweden, 4Department of Public Health and Clinical Medicine- Umeå University, Nutritional Research, Umeå, Sweden

P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

L. Hill1,2, J. Popov1,3, E. Hartung1, M. Moshkovich1,4, M. Figueiredo1,4, N. Pai1,5, McMaster Paediatric FMT Research Program

1Division of Gastroenterology and Nutrition, Department of Paediatrics- McMaster University, Hamilton, Canada, 2Department of Exercise Science and Sports Medicine, University of Cape Town, Cape Town, South Africa, 3College of Medicine and Health, University College Cork, Cork, Ireland, 4Faculty of Health Sciences, McMaster University, Hamilton, Canada, 5Farncombe Family Digestive Health Research Institute, Department of Medicine- McMaster University, Hamilton, Canada

P518 Ulcerative colitis drug development success rates are higher than the industry average

ECCO'20 Vienna

Year: 2020
Authors:

G. Georgiev1, F. Hussain1, M. Copeman2, M. Delegge1, M.B. Gallagher1, T. Stewart1, W. Reinisch3

1IQVIA, Therapeutic Science and Strategy Unit, Raleigh, USA, 2IQVIA, Project Leadership, Raleigh, USA, 3Department of Gastroenterology, University of Vienna, Vienna, Austria

P519 Higher anti-TNF α trough levels are not associated with increased radiological response in perianal fistulising Crohn’s disease: A multicentre study

ECCO'20 Vienna

Year: 2020
Authors:

T. LEE1, L. Gilbert2, A. Srinivasan3, A. Lee4, D. van Langenberg3, C. Martin5, N. Ding1, M. Sparrow2

1Gastroenterology, St Vincent’s Hospital, Melbourne, Australia, 2Gastroenterology, Alfred Health, Melbourne, Australia, 3Gastroenterology, Eastern Health, Melbourne, Australia, 4Eastern Health, Radiology, Melbourne, Australia, 5Monash University, Epidemiology and Public Health, Melbourne, Australia

P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

M.I. Nicolás de Prado1, C. Iniesta Navalón2, R. Gomez Espin1, M. Gil Candel2, L. Serrano Díaz1, L. Rentero Redondo2, J.J. Martinez Crespo1

1Gastroenterology, Reina Sofia Hospital, Murcia, Spain, 2Pharmacology Department, Reina Sofia Hospital, Murcia, Spain

P521 Infection of the anal canal by human papillomavirus in Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

V. Guzela1, C. Sobrado Júnior1, S. Nadal2, C.R. Nadal2, L.L. Villa3, A.P. Gonçalves1, L.R. Boarini1, S.C. Nahas1, I. Cecconello1

1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Gastroenterologia - Divisão de Coloproctologia, São Paulo, Brazil, 2Instituto de Infectologia Emílio Ribas, Departamento de Coloproctologia, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, Laboratório de Inovação em Câncer do Centro de Investigação Translacional em Oncologia, São Paulo, Brazil

P522 Prior pharmacotherapy patterns among patients with IBD in the USA initiating biologic therapy

ECCO'20 Vienna

Year: 2020
Authors:

R. Bornheimer1, S. Hass2, A. NAG3, G. Oster1

1Policy Analysis Inc., Health Economics and Outcomes Research, Brookline, USA, 2H. E. Outcomes, Health Economics and Outcomes Research, Los Angeles, USA, 3Shire- a Takeda company, Health Economics- Outcomes Research and Epidemiology, Lexington, USA